Disparities in Rate, Triggers, and Management in Pediatric and Adult Cases of Suspected Drug-Induced Anaphylaxis in Canada by Gabrielli, Sofianne et al.
Western University
Scholarship@Western
Paediatrics Publications Paediatrics Department
3-2018
Disparities in Rate, Triggers, and Management in
Pediatric and Adult Cases of Suspected Drug-
Induced Anaphylaxis in Canada
Sofianne Gabrielli
Ann E Clarke
University of Calgary
Harley Eisman
Judy Morris
Hôpital du Sacré-Coeur
Lawrence Joseph
McGill University
See next page for additional authors
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons
Citation of this paper:
Gabrielli, Sofianne; Clarke, Ann E; Eisman, Harley; Morris, Judy; Joseph, Lawrence; La Vieille, Sebastien; Small, Peter; Lim, Rodrick;
Enarson, Paul; Zelcer, Michal; Chan, Edmond S; Mill, Chris; and Ben-Shoshan, Moshe, "Disparities in Rate, Triggers, and
Management in Pediatric and Adult Cases of Suspected Drug-Induced Anaphylaxis in Canada" (2018). Paediatrics Publications. 184.
https://ir.lib.uwo.ca/paedpub/184
Authors
Sofianne Gabrielli, Ann E Clarke, Harley Eisman, Judy Morris, Lawrence Joseph, Sebastien La Vieille, Peter
Small, Rodrick Lim, Paul Enarson, Michal Zelcer, Edmond S Chan, Chris Mill, and Moshe Ben-Shoshan
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/184
REVIEW
Disparities in rate, triggers, andmanagement in pediatric and
adult cases of suspected drug-induced anaphylaxis in Canada
Soﬁanne Gabrielli 1, Ann E. Clarke2, Harley Eisman3, Judy Morris4, Lawrence Joseph5,
Sebastien La Vieille6,7, Peter Small8, Rodrick Lim9, Paul Enarson10, Michal Zelcer10, Edmond S. Chan11,
Chris Mill11, & Moshe Ben-Shoshan1
1Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada
2Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
3Department of Emergency Medicine, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada
4Department of Emergency Medicine, Ho^pital du Sacre-Coeur, Montreal, Quebec, Canada
5Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada
6Food Directorate, Health Canada, Ottawa, Ontario, Canada
7Departement sciences des aliments, Faculte des sciences de l'agriculture et de l'alimentation, Universite Laval, Quebec City, Quebec, Canada
8Division of Allergy and Clinical Immunology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
9Department of Paediatrics and Emergency Medicine, Children's Hospital at London Health Science Centre, London, Ontario, Canada
10Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
11Division of Allergy and Immunology, Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia,
Canada
Keywords
Anaphylaxis, anti-bacterial agents, anti-
inflammatory agents (non-steroidal), drug
hypersensitivity, skin tests
Correspondence
Sofianne Gabrielli, M.Sc (c),
Division of Pediatric Allergy and Clinical
Immunology,
Department of Pediatrics,
McGill University Health Centre,
1001 Boul. Decarie, Montreal, Quebec,
Canada, H3A 3J1.
Tel: þ1 (514) 209-4600
Fax: þ1 (514) 412-4288
E-mail: sofiannegabrielli@gmail.com
Funding information
This research was supported by AllerGen NCE
and Health Canada.
Received: 12 June 2017; Revised: 21
September 2017; Accepted: 22 September
2017
Final version published online 1 November
2017.
Immunity, Inflammation and Disease
2018; 6(1): 3–12
doi: 10.1002/iid3.201
Abstract
Introduction: Data is sparse on drug-induced anaphylaxis (DIA) and there have
not been studies assessing the differences in clinical characteristics and
management of DIA between adults and children.
Objective:We assessed the percentage, diagnosis, and management of DIA among
all anaphylaxis visits in three pediatric and one adult emergency departments (ED)
across Canada.
Methods:Children presenting to theMontreal Children’s Hospital (MCH), British
Columbia Children’s Hospital (BCCH), and Children’s Hospital at LondonHealth
Sciences Center and adults presenting to Ho^pital du Sacre-Coeur with anaphylaxis
were recruited as part of the Cross-Canada Anaphylaxis Registry. A standardized
data form documenting the reaction and management was completed and patients
were followed annually to determine assessment by allergist and use of
confirmatory tests.
Results: From June 2012 to May 2016, 51 children were recruited from the
pediatric centers and 64 adults from the adult center with drug-induced
anaphyalxis. More than half the cases were prospectively recruited. The percentage
of DIA among all cases of anaphylaxis was similar in all three pediatric centers but
higher in the adult center inMontreal. Most reactions in children were triggered by
non-antibiotic drugs, and in adults, by antibiotics. The majority of adults and a
third of children did not see an allergist after the initial reaction. In those that did
see an allergist, diagnosis was established by either a skin test or an oral challenge in
less than 20% of cases.
Conclusions:Our results reveal disparities in rate, culprit, andmanagement of DIA
in children versus adults. Further, most cases of suspected drug allergy are not
appropriately diagnosed. Guidelines to improve assessment and diagnosis of DIA
are required.
3© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
Introduction
Drug-induced anaphylaxis (DIA) is a life-threatening
allergic reaction involving at least two organ systems and/
or hypotension triggered by a drug exposure [1, 2]. Studies
report that eight out of one million people will have DIA
yearly [3], and that 1 case per 4000 Emergency Department
(ED) visits will be due to DIA [4]. A recent study conducted
in Australia found that hospital admission rates due to DIA
have increased by 6.8% per year over 16 years and that DIA
was the leading cause of fatal anaphylaxis [5]. In the United
States, drugs were also found to be the most common cause
of fatal anaphylaxis with fatalities significantly increasing
from 1999 to 2010 [6].
Currently there are no prospective studies assessing the
clinical characteristics and management of DIA. Further-
more, no studies so far have assessed differences in clinical
characteristics and management of DIA between pediatric
and adult EDs. We assessed the percentage, demographics,
clinical characteristics, andmanagement including the use of
confirmatory tests to diagnose DIA cases treated in three
pediatric EDs and one adult ED across Canada.
Methods
Study design
From June 2012 to May 2016, children presenting to the
Montreal Children’s Hospital (MCH) ED and adults
presenting to the Ho^pital du Sacre-Coeur (HSC) EDs with
anaphylaxis were recruited as part of the Cross-Canada
Anaphylaxis Registry (C-CARE). Over a 2-year period, from
June 2014 to May 2016, children presenting to the British
Columbia Children’s Hospital (BCCH) and Children’s
Hospital at London Health Sciences Centre (LHSC) EDs
with anaphylaxis were recruited for C-CARE. The MCH and
HSC are tertiary hospitals located in Montreal, Quebec that
treat approximately 80,000 and 60,000 patients annually in
their EDs, respectively. The BCCH is a tertiary pediatric
center located in Vancouver, British Columbia that treats
approximately 45,000 patients annually in their ED. The
LHSC is a teaching hospital located in London, Ontario,
treating 36,000 patients annually in their ED.
This study followed the RECORD guideline for observa-
tional studies. Data on patients were collected either
prospectively or retrospectively. Prospective data was
collected at the time of patient presentation. The treating
physician identified cases of anaphylaxis and with the help of
a trained research member obtained consent and completed
a standardized data entry form documenting symptoms,
triggers, and management of anaphylaxis. Data on missed
cases that were not recruited at the time of presentation to
the ED was collected retrospectively. In brief, all cases
presenting to the ED were reviewed according to ICD-10
codes related to allergic reactions/anaphylaxis based on a
previously validated algorithm [7, 8]. Anaphylaxis was
defined as the involvement of two or more organ systems
after exposure to a possible allergen or hypotension after
exposure to a known allergen [9]. Only prospective and
retrospective cases meeting the definition of anaphylaxis as
determined by two independent reviewers (SG and MBS)
were included. Consenting prospective patients or families
(in the case of children) were contacted annually to
determine if they had been seen by an allergist and if the
culprit drug was confirmed through the use of skin tests or
an oral challenge. Treating allergists were contacted and
asked to provide documented results of skin tests and
challenges. Data regarding the use of confirmatory tests for
retrospective cases was obtained through chart review for
patients who had been seen at the study centers. The study
was approved by the McGill University Ethics Committee,
the Research Ethics Board of theHo^pital du Sacre-Coeur, the
University of British Columbia/Children’s, and Women’s
Health Center of British Columbia Research Ethics Board
and Health Science Research Ethics Board at Western
University.
Statistical analysis
All statistical analyses were done using R version 3.2.2. (R
Core Team [2013]; R: A language and environment for
statistical computing; R Foundation for Statistical Comput-
ing, Vienna, Austria). Percentages with a 95% confidence
intervals (CI, binomial or multinomial for variables with
more than two categories), were used to assess patient
demographics, symptoms, culprit drugs, reaction severity,
management, and percentage of DIA cases. Univariate and
multivariate logistic regression models were compared to
estimate factors associated with reaction severity, assessment
by an allergist, and established drug allergy for the pediatric
and adult EDs. All variables, excluding age and follow-up
time, were dichotomized. Given the difference in catchment
population between sites and that previous studies suggest
differences regarding the risk of drug allergy as well as the
culprit between adults and children [10], separate regression
models for each site were fit.
Results
Temporal trends in the percentage of DIA among all
anaphylaxis cases (Table 1 and Fig. 1).
Pediatric cases
As shown in Table 1, the percentages of DIA among all cases of
anaphylaxis (1.6–7%) and among all ED visits (0.003–0.01%) did
not differ and did not change significantly from year to year
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between the three pediatric EDs. There were no conclusive
differences in thepercentageofDIAamongall casesofanaphylaxis
between the three pediatric EDs over 2 years (Table 1).
Adult cases
At the adult ED, the percentage of DIA among all cases of
anaphylaxis (18.3–22.1%) and among all ED visits (0.02–
0.03%) also showed no change over a 4-year period
(Table 1). However, the percentage of DIA among all cases
of anaphylaxis was substantially higher in the adult center
versus the pediatric centers (Table 1).
Demographics and clinical characteristics (Table 2 and
Fig. 2).
Pediatric cases
As shown in Table 2, 51 pediatric patients presented to the
three pediatric EDs with DIA. Demographic characteristics
(age, sex), presence of co-morbidities (e.g., asthma), culprit
drugs, severity of anaphylaxis, andmanagement were similar
in the three pediatric centers. Hence, all pediatric cases were
assessed as one group hereafter. Nearly half of the children,
Table 1. Percentage and percent difference of anaphylaxis and drug-induced anaphylaxis cases.
Variable (%,
95%CI) Ho^pital Sacre-Coeur Montreal Children's Hospital
British Columbia
Children's Hospital
Children's Hospital at London Health
Science Center
Percentage of anaphylaxis among all ED cases
2012–2013 0.11% (0.089%, 0.15%) 0.35% (0.31%, 0.40%) – –
2013–2014 0.16% (0.13%, 0.20%) 0.33% (0.29%, 0.37%) – –
2014–2015 0.15% (0.13%, 0.19%) 0.42% (0.38%, 0.47%) 0.34% (0.29%, 0.40%) 0.097% (0.068%, 0.14%)
2015–2016 0.11% (0.089%, 0.15%) 0.38% (0.34%, 0.42%) 0.40% (0.34%, 0.46%) 0.12% (0.089%, 0.17%)
Differences
Years 1–2 0.047% (0.019%, 0.091%) 0.024% (0.082%, 0.034%) – –
Years 2–3 0.0061% (0.053%, 0.041%) 0.094% (0.034%, 0.15%) – –
Years 3–4 0.041% (0.084%, 0.0030%) 0.046% (0.11%, 0.017%) – –
Total (Years
1–4)
0.00016% (0.039%, 0.039%) 0.024% (0.036%, 0.085%) 0.055% (0.024%, 0.14%) 0.024% (0.028%, 0.077%)
Percentage of DIA among all cases of anaphylaxis
2012–2013 20.0% (11.5%, 32.1%) 2.8% (1.3%, 5.7%) – –
2013–2014 18.3% (11.3%, 27.9%) 3.2% (1.6%, 6.3%) – –
2014–2015 21.1% (13.5%, 31.2%) 3.5% (1.9%, 6.1%) 2.5% (0.8%, 6.8%) 3.0% (0.16%, 17.5%)
2015–2016 22.1% (13.3%, 34.1%) 3.6% (1.9%, 6.6%) 1.6% (0.41%, 5.0%) 7.0% (1.8%, 20.1%)
Differences
Year 1–2 1.7% (15.5%, 12.1%) 0.4% (2.8%, 3.6%) – –
Year 2–3 2.8% (9.8%, 15.4%) 0.2% (2.8%, 3.3%) – –
Year 3–4 0.9% (13.0%, 14.9%) 0.2% (2.8%, 3.2%) – –
Total (Year
1–4)
2.1% (13.3%, 17.4%) 0.8% (2.4%, 4.0%) 0.94% (4.6%, 2.7%) 0.70% (16.2%, 8.3%)
Percentage of DIA among all ED visits
2012–2013 0.023% (0.013%, 0.040%) 0.010% (0.0047%, 0.021%) – –
2013–2014 0.029% (0.018%, 0.048%) 0.011% (0.0052%, 0.021%) – –
2014–2015 0.033% (0.020%, 0.052%) 0.015% (0.0079%, 0.026%) 0.0086% (0.0028%,
0.024%)
0.0029% (0.0002%, 0.019%)
2015–2016 0.025% (0.015%, 0.043%) 0.014% (0.0072%, 0.025%) 0.0063% (0.0063%,
0.020%)
0.0085% (0.0022%, 0.027%)
Differences
Years 1–2 0.0065% (0.014%, 0.027%) 0.00064% (0.0099%, 0.011%) – –
Years 2–3 0.0033% (0.019%, 0.025%) 0.0039% (0.0081%, 0.016%) – –
Years 3–4 0.0075% (0.029%, 0.014%) 0.00097% (0.014%, 0.012%) – –
Total (Years
1–4)
0.0023% (0.017%, 0.022%) 0.0036% (0.083%, 0.016%) 0.0023% (0.016%,
0.011%)
0.0055% (0.0085%, 0.020%)
Figure 1. The percentage of drug-induced anaphylaxis cases among all
cases of anaphylaxis per year in the adult and pediatric emergency
departments. Error bars represent standard deviation.
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Table 2. Characteristics of patients presenting to the emergency department with drug-induced anaphylaxis.
Adult Patients (N¼ 64) Pediatric Patients (N¼ 51)
Variable (%, 95%CI) No. (%) 95%CI No. (%) 95%CI Difference
Age at reaction (median, IQR) 49.4 (40.1, 62.9) 8.00 (3.79, 15.36) 41.4
Age at reaction (mean, standard
deviation)
48.9 (14.8) 8.95 (5.9) 39.95 (35.9, 44.0)
Sex (% males) 18 (28.1%) 17.9%,
41.0%
27 (52.9%) 38.6%,
66.8%
24.8% (44.2%, 5.5%)
Medication type
Antibiotics 37 (57.8%) 44.8%,
69.8%
19 (37.3%) 24.5%,
51.9%
20.6% (0.8%, 40.3%)
Beta-Lactams 18 (28.1%) 17.2%,
41.3%
16 (31.4%) 17.6%,
45.5%
3.2% (21.8%, 15.4%)
Macrolides 2 (3.1%) 0%, 16.3% 2 (3.9%) 0%, 18.1% 0.8% (8.4%, 6.8%)
Quinolones 13 (20.3%) 9.4%, 33.5% 1 (2.0%) 0%, 16.1% 18.4% (6.0%, 30.7%)
Other antibiotics 4 (6.3%) 0%, 19.4% 0 (0%) 0%, 14.2% 6.3% (1.4%, 13.9%)
Non-antibiotic drugs 27 (42.2%) 30.2%,
55.2%
32 (62.7%) 48.1%,
75.5%
20.6% (40.3%, 0.8%)
NSAIDs 13 (20.3%) 9.4%, 33.5% 11 (21.6%) 7.8%, 35.7% 1.3% (17.5%, 15.0%)
Contrast agents 2 (3.1%) 0%, 16.3% 2 (3.9%) 0%, 18.1% 0.8% (8.4%, 3.9%)
Other non-antibiotic drugsa 12 (18.8%) 7.8%, 31.9% 19 (37.3%) 23.5%,
51.4%
18.5% (36.6%, -0.4%)
Known drug allergy 17 (26.6%) 16.7%,
39.3%
4 (8.3%) 2.7%, 20.9% 18.2% (3.1%, 33.4%)
Known food allergy 8 (12.5%) 5.9%, 23.7% 12 (25.0%) 14.1%,
39.9%
12.5% (29.0%, 4.0%)
Known asthma 6 (9.4%) 3.9%, 19.9% 10 (20.8%) 11.0%,
35.4%
11.5% (26.8%, 3.9%)
Reaction type
Mildb 0 (0%) 0%, 9.7% 13 (25.5%) 3.7%, 37.3% 25.5% (39.2%, 11.8%)
Moderatec 53 (82.8%) 75.0%,
92.1%
36 (70.6%) 58.8%,
82.4%
12.2% (5.1%, 29.5%)
Severed 11 (17.2%) 9.4%, 26.5% 2 (3.9%) 0%, 15.7% 13.3% (0.8%, 25.7%)
Exposure route
Ingestion 60 (93.8%) 89.1%,
98.7%
38 (74.5%) 64.7%,
86.8%
19.2% (4.1%, 34.4%)
Contacte 0 (0%) 0%, 4.9% 3 (5.9%) 0%, 18.2% 5.9% (14.1%, 2.3%)
Inhaled 1 (1.6%) 0%, 6.5% 1 (2.0%) 0%, 14.3% 0.4% (5.7%, 4.9%)
Parenteral 3 (4.7%) 0%, 9.6% 9 (17.6%) 7.8%, 30.0% 13.0% (26.4%, 0.5%)
Treatment in ED
Epinephrine 33 (51.6%) 38.8%,
64.1%
30 (58.8%) 44.2%,
72.1%
7.3% (27.3%, 12.7%)
Antihistamines 53 (82.8%) 70.9%,
90.7%
26 (51.0%) 36.8%,
65.0%
31.8% (13.5%, 50.1%)
Steroids 53 (82.8%) 70.9%,
90.7%
16 (31.4%) 19.5%,
46.0%
51.4% (33.9%, 68.9%)
aOther Non-Antibiotics Drugs: Children: Marijuana, Local anesthetic (Prilocaine), Antihistamine (Claritin), Corticosteroids (Dexamethasone and
Prednisone), N-acetyl cysteine, Zantac, Oralair, Triptan, Cyclopentolate eye drops, Wilate (Factor 8), Morphine, Vicks VapoDrops, Granulocyte-
macrophage colony-stimulating factor (GM-CSF), Atypical Antipsychotic (Risperdal). Adults: Tylenol, Codeine, Cocaine, Alpha1-Adrenergic Receptor
Antagonist (Terazosin), Antifungal Medication (Fluconazole), Lactase (Lacteeze), Benylin cough syrup, Angiotensin-converting Enzyme (ACE) Inhibitor
(Ramipril), Protein Pump Inhibitor (Pantoprazole), Anticonvulsant (Lyrica).
bSymptoms include urticaria, erythema, angioedema, oral pruritus, nausea, nasal congestion, sneezing, rhinorrhea, or throat tightness [11].
cSymptoms include crampy abdominal pain, diarrhea, recurrent vomiting, dyspnea, stridor, cough, wheeze, or “light-headedness” [11].
dSymptoms include cyanosis, hypoxia, respiratory arrest, hypotension, dysrhythmia, confusion, or loss of consciousness [11].
eCyclopentolate eye drops.
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25 patients (49.0%), were recruited prospectively, of which
the mean follow-up time to determine if the patients had
been assessed by an allergist was 1.26 years (Supplementary
Table S1). The majority of the reactions were triggered by
non-antibiotic drugs (62.7%), of which the main culprit was
non-steroidal anti-inflammatory drugs (NSAIDs, 21.6%)
(Table 2). Reactions attributed to antibiotics accounted for
37.3% of the reactions, with b-lactams being the most
frequently suspected (31.4%). Only four children reported
having a history of drug allergy, with one child reacting to the
known drug culprit.
Adult cases
From June 2012 to May 2016, 64 adults presented with DIA
of which 52 (81.3%) were recruited prospectively, with a
mean follow-up of 1.33 years (Supplementary Table S1).
Unlike pediatric cases, the majority of reactions occurred in
females.
Most reactions were attributed to antibiotics (57.8%),
mainly b-lactams (28.1%) and quinolones (20.3%). Reac-
tions attributed to non-antibiotic drugs accounted for 42.2%
of the reactions, NSAIDs being the most frequently involved
(20.3%) (Table 2). Seventeen adults reported having a
history of drug allergy, of which three had anaphylaxis
associated with re-exposure to a drug they were known to be
allergic to. Theremore severe reactions in adults and a higher
percentage had a known drug allergy.
Management in the ED (Table 2).
Pediatric cases
At the three pediatric centers across Canada, both epineph-
rine and antihistamines were used to treat over half of the
reactions (Table 2). Steroids were used for treatment in 16
(31.4%) patients (Table 2).
Adult cases
About half of the adults were treated with epinephrine.
However, unlike pediatric cases, themajority of cases in adults
were treated with antihistamines and/or steroids (Table 2)
Allergy assessment (Supplementary Table S2 and Fig. 3).
Pediatric cases
All drugs
Consent for prospective follow-up was given for 25 pediatric
cases of suspected DIA. Data for 20 retrospective cases was
Figure 2. Comparison of the percentage of antibiotic versus non-
antibiotic drug cases among all cases of drug-induced anaphylaxis cases
in the adult and pediatric emergency departments over a 4-year period.
Error bars represent standard deviation.
Figure 3. Comparison of the percentage of cases that were assessed and conﬁrmed by an allergist, cases assessed by an allergist only, and cases not
assessed among all visits of drug-induced anaphylaxis in the adult and pediatric emergency departments over a 4-year period. Error bars
represent standard deviation.
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collected by chart review of the allergy visits. After the initial
ED visit, 30 (68.2%) children had seen an allergist for
assessment andmedical recordswere obtained for all children.
Fourteen children were skin tested and nine children were
subjected to an oral challenge with the suspected drug, either
after negative skin test (5, 55.5%), or without prior skin test
(4, 44.4%). Drug allergy was diagnosed in 4 (22.2%) of these
children, based on positive responses in skin test (2, 14.3%)or
oral challenge (2, 22.2%) (Supplementary Table S2).
Antibiotics
Of the 18 (40.0%) patients that presented to the pediatric
centers with anaphylaxis to antibiotics, only 10 (55.5%)
patients had seen an allergist for assessment. Of the 10
children, 7 underwent skin testing, of which 1 was positive
to ceftriaxone by intradermal skin testing. Among the six
with a negative skin test, two proceeded to a graded oral
challenge, which was positive in one case to amoxicillin. Of
the three children who did not have a skin test, two
underwent an oral challenge without prior skin testing, of
which one patient had a positive challenge to clarithro-
mycin. One patient did not undergo any testing despite
having seen an allergist.
Non-antibiotics
Among the 27 (60.0%) pediatric patients who reacted to
non-antibiotic drugs, 20 (74.1%) had been assessed by an
allergist. Seven patients underwent skin testing of which 6
were negative. The positive skin test was to cyclopentolate.
Of the six patients with negative skin tests, three proceeded
with a graded oral challenge, which were all negative. Two
patients underwent a graded oral challenge without prior
skin testing, which were both negative.
Adult cases
All drugs
Among the 64 adult patients with suspected DIA, 52
(81.3%) patients were prospective and eligible for follow-
up. We were able to reach 37 patients (71.2%) of the 52
consenting patients. Less than a third had been assessed by
an allergist after the ED visit. Medical charts were obtained
for over 50.0% of adults who had seen an allergist
(Supplementary Table S2). Of the six (54.5%) adult
patients who were assessed by an allergist and provided
consent to provide medical records, only two underwent
skin testing of which one was reported by the patient as
positive to a contrast agent. The patient with the negative
skin test had a graded oral challenge which was positive to
the antibiotic cefadroxil. Therefore, drug allergy was
confirmed by skin test in one patient and an oral challenge
in another patient.
Antibiotics
Of the 29 (55.8%) adults who had anaphylaxis to antibiotics,
21 (72.4%) consented to follow-up, of which only 7 (33.3%)
had been assessed by an allergist. Of these seven patients,
four (57.1%) provided consent to provide medical records.
One patient underwent skin testing which was negative and
that same patient underwent a graded oral challenge which
was positive to cefadroxil.
Non-antibiotics
Of the 23 (44.2%)adult prospectivepatientswho reacted tonon-
antibiotic drugs, 16 (69.6%) consented to follow-up, of which
only 3 (18.8%) had been assessed by an allergist. Of these
patients, 2 (66.7%) consented to provide medical records. One
patient underwent skin testing which was positive to a contrast
agent. The second patients did not undergo any testing.
Factors associated with severe DIA, allergy assessment,
and diagnosis of DIA (Supplementary Tables S3–S6).
Pediatric cases
Univariate and multivariate analyses showed that in
pediatric patients, parenteral exposure to drugs was the
main significant risk factor for severe DIA. Age, sex, type of
drug, history of asthma, and/or food allergy were not
associated with severe DIA (Supplementary Table S3).
Among the patients at the three pediatric centers, assessment
by an allergist was more likely in males and in patients
presenting to the ED in Montreal versus the other EDs
(Supplementary Table S5). An established drug allergy by an
allergist through a skin test/challenge wasmore likely in cases
of antibiotic-induced reactions and less likely in younger
children (Supplementary Table S6).
Adult cases
Similarly, among the adult patients, severe DIA was
associated with parenteral exposure when adjusting for
age, sex, type of drug, history of asthma, history of known
drug allergy, and history of known food allergy (Supple-
mentary Table S4).
Discussion
We have conducted the first prospective study assessing
clinical characteristics and diagnosis of DIA in children and
adults in four EDs across Canada. Our study reveals that
while there was no conclusive change in the percentage of
DIA over time in all four centers, the percentage of DIA
among all cases of anaphylaxis is higher in adults than in
children. Further, we report the disparities between reported
DIA and established DIA in children. Themain drug culprits
in adults and children are antibiotics and non-antibiotic
Drug-induced anaphylaxis in children and adults S. Gabrielli et al.
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drugs, respectively, and, in both age groups, there is
substantial underuse of epinephrine. Moreover, our findings
show for the first time that the majority of reported cases of
DIA cases are not appropriately diagnosed.
The higher percentage of DIA in adults compared to
children is consistent with previous retrospective reports
suggesting that DIA occurs more frequently in adults [12].
The increased risk of DIA in adults could be due to greater
exposure to antibiotics over the course of their life and in
particular fluoroquinolones, that are relatively contra-
indicated in children [13]. The frequency of use of antibiotic
drugs in adults compared to children is further exemplified
in Figure 2. Additionally, middle and older aged adults have
a greater risk of drug reactions due to the simultaneous use
of multiple drugs to treat co-morbidities and age-related
changes in pharmacokinetics and pharmacodynamics [14].
While there was no sex dominance for children, fewer cases
of DIA among adult males were found (Table 2), which is in
line with other studies [15] and may be explained by the
effects of estrogen on mediators of anaphylaxis during the
reproductive years in females [15].
In our population, very few adult patients consulted an
allergist after the initial ED visit. The low percentage of
adults and children assessed for DIA may be due to
patient-related factors or due to the factors related to the
Canadian heath system. Studies suggest that young adults,
between the ages of 17–44 years, are the least compliant
with using referrals to be assessed by medical special-
ists [16], which could be attributed to patients’ other
priorities and inability to take time off work [17, 18].
Health system-related factors that could contribute to
under assessment of DIA include low number of allergists
in Canada and long waiting time for specialist assess-
ment [17]. Regardless of its cause, non-confirmed drug
allergy may lead to mislabeling of patients [19]. Mislabel-
ing of patients has been associated with increased use of
alternative antibiotics [20–22], increased risk of acquiring
antibiotic-resistant infections [19–22], such as C. difficile,
vancomycin-resistant enterococci (VRE), and methicillin-
resistant Staphylococcus aureus (MRSA), significantly
longer hospital stays [19, 21], increased healthcare
costs [19], and increased mortality [23].
Our results indicate that majority of suspected DIA cases
in adults and children are not assessed appropriately by
allergists. Current guidelines recommend the use of skin tests
and oral challenges to diagnose suspected cases of antibiotic
allergy [24]. Studies suggest that skin tests might be useful
for diagnosing penicillin allergy [25], however, their role in
amoxicillin allergy, the most common penicillin derivative,
is less clear [26]. Further, skin tests are not standardized for
most antibiotics [24] and studies report poor predictive
values for antibiotics [24] and NSAIDs [27] regarding skin
tests. In the absence of sensitive and accurate skin tests, our
results support the use of challenges only to establish the
diagnosis of DIA.
An interesting finding is the relatively high percentage of
reported fluoroquinolone DIA in adults. Recent studies have
found that the number of immediate-type reactions to
quinolones, especially moxifloxacin, increased over the past
few years [28, 29], which could be a result of the updated
treatment guidelines recommending the use of moxifloxacin
as first line treatment in the management of bacterial
respiratory infections, including sinusitis and pneumonia in
adults [30]. Allergy to fluoroquinolone is rarely established
likely due to the absence of standardized skin tests [29] and
the risks related to conducting a drug challenge [31].
We demonstrate that NSAIDs are a common culprit of
DIA in children and adults. NSAIDs were reported to be
major triggers of DIA in other studies [32–34], however
none of these studies evaluated the long-term follow-up and
assessment of those presenting with anaphylaxis to NSAIDs
in the ED. The high percentage of reactions to NSAIDs could
be explained by the increased consumption and high
frequency of prescriptions to treat pain and fever [34, 35].
There are no standardized skin tests for the diagnosis of most
NSAID-induced anaphylaxis [32]. Recent studies suggest
that suspected cases of NSAID allergy should be assessed
with oral challenges [24, 27, 36], however, only a few
challenges were conducted in our population. The under-
utilization of challenges in our population is likely
attributable to the fact that such challenges are usually
only performed in a hospital, under the supervision of an
allergist [24] and there is limited access and long wait times
for specialist assessment in some areas of Canada [17]. It is
possible that in cases of DIA attributed to NSAIDS with
negative challenges, NSAIDs may have acted as cofactors or
augmenting factors rather than as a sole culprit for
anaphylaxis [15]. It is also possible that cases reported as
DIA, with a negative challenge, are likely attributable to the
presence of unidentifiable factors or to conditions mimick-
ing anaphylaxis, such as viral infections, food poisoning, or
other toxic effects of medications [37].
In our study, the majority of children from the pediatric
centers were assessed by an allergist after the initial
reaction. Patients recruited from the Montreal pediatric
center and males were more likely to be assessed by an
allergist. The presence of the large allergy division and a
specific drug allergy clinic at the MCH allows for greater
access to an allergy specialist compared to the other
centers. In addition, given that a large antibiotic registry
exists only in the Quebec center and given numerous
publications related to this specific registry, there may be
higher awareness for referring to allergy specialists at this
center [24]. Our finding that DIA is more likely established
with a skin test and/or challenge in cases of antibiotic-
induced reactions is not surprising given the availability of
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skin tests for antibiotics (mainly b-lactams) versus non-
antibiotic drugs [38]. It is also possible that in younger
children the diagnosis of DIA is less likely established
because physicians will be more hesitant to conduct a drug
challenge in young children who are less able to verbalize
their complaints.
Our study found that receiving parenteral drug
treatment was associated with more severe reactions in
both adults and children. It is reported that the vast
majority of anaphylaxis fatalities have occurred in patients
treated with intramuscular or intravenous antibiotic
preparations, rather than oral [39, 41]. This could be
related to receiving a large amount of allergen into the
body over a relatively short period of time, which reaches a
high concentration in body organs [40]. Given the
association of a severe reaction with parenteral adminis-
tration of the drug in children and adults, caregivers
should be made aware of the risk for severe anaphylaxis
associated with those requiring IV treatment.
Our study has potential limitations. In the case of a
negative skin test and negative oral graded challenge, it is
possible that cases defined as DIA were actually idiopathic
or caused by other unidentified factors. However, this
limitation is shared with all studies assessing DIA. Our
unique study design allowed for follow-up of prospective
patients and the collection of data on established cases of
DIA. Another important limitation is due to the fact that
many patients did not see an allergist and many did not
have confirmatory tests to establish the cause of suspected
DIA. These cases might have been misclassified, however,
this is a limitation of all previous studies assessing DIA in
the ED. Due to the similarities in terms of medication type,
a history of drug allergy, food allergy, and asthma, and
severity of reaction between cases that were confirmed and
cases that were not confirmed (Tables S7 and S8), this
misclassification was unlikely to affect our conclusions.
Further, in contrast to other studies on DIA in the ED, our
study included a prospective arm that enabled us for the
first time to determine the low percentage of established
cases and the need for better diagnostic strategies. Given
ethics restrictions, we were not allowed to actively assess
patients and conduct challenges. Adults were included
from one center, since this was the only center
collaborating to recruit patients prospectively. Given that
the catchment population was based on only four sites
across Canada, it is possible that our study cannot be
generalized to the entire Canadian pediatric and adult
populations. Although we aimed to recruit all patients
prospectively, almost 50% of the pediatric patients and
20% of the adult patients were identified retrospectively.
Given that we did not have permission to contact
retrospective cases, data on assessment of these patients
was only available via chart review of the allergy visit.
However, demographic and clinical characteristics of DIA
between retrospective and prospective patients were
similar (Supplementary Table S1) and hence we believe
that our findings are valid. Finally, our sample size
prevented accurate estimation of the temporal change in
percentage of DIA.
In conclusion, this is the first study to assess clinical
characteristics and long-term assessment of DIA present-
ing in the EDs across Canada. Our study emphasizes the
need for uniform guidelines in the management of DIA in
the ED such as the regulated use of epinephrine and
qualified diagnosis of the condition by trained allergists in
order to avoid recurrences and reduce patient morbidity.
Future studies elucidating the pathogenesis of DIA and
evaluating appropriate and efficient confirmatory tests will
contribute to bridging the gaps related to the management
of DIA.
Conflicts of Interest
None.
References
1. Blanca-Lopez, N., M. del Carmen Plaza-Seron, J. A.
Cornejo-Garcı´a, J. R. Perkins, G. Canto, and M. Blanca.
2015. Drug-induced anaphylaxis. Curr. Treat. Options
Allergy 2:169–182.
2. Banerji, A., S. Rudders, S. Clark, W. Wei, A. A. Long, and
C. A. Camargo, Jr. 2014. Retrospective study of drug-induced
anaphylaxis treated in the emergency department or hospital:
patient characteristics, management, and 1-Year follow-up. J.
Allergy Clin. Immunol. 2:46–51.
3. Ribeiro-Vaz, I., J. Marques, P. Demoly, J. Polonia, and E. R.
Gomes. 2013. Drug-induced anaphylaxis: a decade review of
reporting to the Portuguese Pharmacovigilance Authority.
Eur. J. Clin. Pharmacol. 69:673–681.
4. MoroMoro,M.,M. A. Tejedor Alonso, J. EstebanHernandez,
M. V. M. Mugica Garcı´a, A. Rosado Ingelmo, and C. Vila
Albelda. 2011. Incidence of anaphylaxis and subtypes of
anaphylaxis in a general hospital emergency department. J.
Investig. Allergol. Clin. Immunol. 21:142–149.
5. Mullins, R. J., B. K. Wainstein, E. H. Barnes, W. K. Liew, and
D. E. Campbell. 2016. Increases in anaphylaxis fatalities in
Australia from1997 to 2013. Clin. Exp. Allergy 46:1099–1110.
6. Jerschow, E., R. Y. Lin, M. M. Scaperotti, and A. P. McGinn.
2014. Fatal anaphylaxis in the United States 1999-2010:
temporal patterns and demographic associations. J. Allergy
Clin. Immunol. 134:1318–1328.
7. Hochstadter, E., A. Clarke, S. De Schryver, S. LaVieille, R.
Alizadehfar, L. Joseph, H. Eisman, and M. Ben-Shoshan.
2016. Increasing visits for anaphylaxis and the benefits of
early epinephrine administration: a 4-year study at a pediatric
Drug-induced anaphylaxis in children and adults S. Gabrielli et al.
10 © 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
emergency department in Montreal, Canada. J. Allergy Clin.
Immunol. 137:1888–1890. e4.
8. Vetander, M., D. Helander, C. Flodstr€om, E. Ostblom, T.
Alfven, D. H. Ly, G. Hedlin, G. Lilja, C. Nilsson, and M.
Wickman. 2012. Anaphylaxis and reactions to foods in
children—a population-based case study of emergency
department visits. Clin. Experiment. Allergy 42:568–577.
9. Sampson, H. A., A. Mu~noz-Furlong, R. L. Campbell, N. F.
Adkinson Jr, S. A. Brock, A. Branum, S. G. Brown, C. A.
Camargo Jr, R. Cydulka, S. J. Galli, et al. 2006. Second
symposium on the definition and management of anaphy-
laxis: summary report—Second National Institute of
Allergy and Infectious Disease/Food Allergy and
Anaphylaxis Network symposium. J. Allergy Clin. Immunol.
117:391–397.
10. Harandian, F., D. Pham, and M. Ben-Shoshan. 2016. Positive
penicillin allergy testing results: a systematic review andmeta-
analysis of papers published from 2010 through 2015.
Postgrad. Med. 128:1–6.
11. Brown, S. G. A. 2004. Clinical features and severity grading of
anaphylaxis. J. Allergy Clin. Immunol. 114:371–376.
12. Tejedor Alonso, M. A., M. Moro Moro, and M. V. Mugica
Garcı´a. 2015. Epidemiology of anaphylaxis. Epidemiology of
anaphylaxis. Clin. Exp. Allergy. 45:1027–1039.
13. Bacci, C., L. Galli, M. De Martino, and E. Chiappini. 2015.
Fluoroquinolones in children: update of the literature. J.
Chemother. 27:257–265.
14. Heng, Y. K., and Y. L. Lim. 2015. Cutaneous adverse drug
reactions in the elderly. Curr. Opin. Allergy Clini. Immunol.
15:300–307.
15. Munoz-Cano, R., C. Picado, A. Valero, and J. Bartra. 2016.
Mechanisms of anaphylaxis beyond IgE. J. Invest. Allergology
Clin. Immunol. 26:73–82. quiz 2p following 83.
16. van Dijk, C. E., J. D. de Jong, R. A. Verheij, T. Jansen, J. C.
Korevaar, and D. H. de Bakker. 2016. Compliance with
referrals to medical specialist care: patient and general
practice determinants: a cross-sectional study. BMC Fam.
Pract. 17:11.
17. Harrington, D. W., K. Wilson, and M. W. Rosenberg. 2014.
Waiting for a specialist consultation for a new condition in
Ontario: impacts on patients’ lives. Healthcare Policy¼Poli-
tiques de sante. 9:90–103.
18. Jin, J., G. E. Sklar, V. Min Sen Oh, and S. Chuen Li. 2008.
Factors affecting therapeutic compliance: a review from the
patient’s perspective. Therap. Clin. Risk Manage.
4:269–286.
19. Macy, E., and R. Contreras. 2014. Health care use and serious
infection prevalence associated with penicillin ‘‘allergy’’ in
hospitalized patients: a cohort study. J. Allergy Clin.
Immunol. 133:790–796.
20. Solensky, R., H. S. Earl, and R. S. Gruchalla. 2000. Clinical
approach to penicillin-allergic patients: a survey. Ann.
Allergy. Asthma. Immunol. 84:329–333.
21. Martinez, J. A., R. Ruthazer, K. Hansjosten, L. Barefoot, and
D. R. Snydman. 2003. Role of environmental contamination
as a risk factor for acquisition of vancomycin-resistant
enterococci in patients treated in a medical intensive care
unit. Arch. Intern. Med. 163:1905–1912.
22. Pepin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P.
Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V.
Primeau, et al. 2005. Emergence of fluoroquinolones as the
predominant risk factor for Clostridium difficile-associated
diarrhea: a cohort study during an epidemic in Quebec. Clin.
Ifect. Dis. 41:1254–1260.
23. McDanel, J. S., E. N. Perencevich, D. J. Diekema, L. A.
Herwaldt, T. C. Smith, E. A. Chrischilles, J. D. Dawson, L.
Jiang, M. Goto, and M. L. Schweizer. 2015. Comparative
effectiveness of beta-lactams versus vancomycin for treatment
of methicillin-susceptible Staphylococcus aureus blood-
stream infections among 122 hospitals. Clin. Infect. Dis.
61:361–367.
24. Mill, C., M. Primeau, E. Medoff, C. Lejtenyi, A. O’Keefe, E.
Netchipourouk, A. Dery, and M. Ben-Shoshan. 2016.
ASsessing the diagnostic properties of a graded oral
provocation challenge for the diagnosis of immediate and
nonimmediate reactions to amoxicillin in children. JAMA
Pediatrics. 170:e160033.
25. Mirakian, R., S. C. Leech, M. T. Krishna, A. G. Richter, P. A.
Huber, S. Farooque, N. Khan, M. Pirmohamed, A. T. Clark,
S. M. Nasser, et al. 2015. Management of allergy to penicillins
and other beta-lactams. Clin. Exp. Allergy 45:300–327.
26. Blanca, M., A. Romano, M. J. Torres, P. Demoly, and A.
DeWeck. 2007. Continued need of appropriate betalactam-
derived skin test reagents for the management of allergy to
betalactams. Clin. Exp. Allergy 37:166–173.
27. Cortellini, G., A. Romano, A. Santucci, A. Barbaud, S. Bavbek,
D. Bignardi, M. Blanca, P. Bonadonna, M. T. Costantino, J. J.
Laguna, et al. 2016. Clinical approach on challenge and
desensitization procedures with aspirin in patients with
ischemic heart disease and NSAID hypersensitivity. Allergy
72:498–506.
28. Blanca-Lopez, N., A. Ariza, I. Dona, C. Mayorga, M. I.
Montanez, J. Garcia-Campos, F. Gomez, C. Rondon, M.
Blanca, and M. J. Torres. 2013. Hypersensitivity reactions to
fluoroquinolones: analysis of the factors involved. Clin. Exp.
Allergy 43:560–567.
29. Blanca-Lopez, N., I. Andreu, and M. J. Torres Jaen. 2011.
Hypersensitivity reactions to quinolones. Curr. Opin. Allergy
Clin. Immunol. 11:285–291.
30. Frei, C. R., R. T. Attridge, E. M. Mortensen, M. I. Restrepo, Y.
Yu, C. U. Oramasionwu, J. L. Ruiz, and D. S. Burgess. 2010.
Guideline-concordant antibiotic use and survival among
patients with community-acquired pneumonia admitted to
the intensive care unit. Clin. Ther. 32:293–299.
31. Romano, A., M. Blanca, M. J. Torres, A. Bircher, W. Aberer,
K. Brockow, W. J. Pichler, P. Demoly, ENDA, and EAACI.
S. Gabrielli et al. Drug-induced anaphylaxis in children and adults
© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. 11
2004. Diagnosis of nonimmediate reactions to beta-lactam
antibiotics. Allergy. 59:1153–1160.
32. Kowalski, M. L., K. Woessner, and M. Sanak. 2015.
Approaches to the diagnosis and management of patients
with a history of nonsteroidal anti-inflammatory drug-related
urticaria and angioedema. J. Allergy Clin. Immunol.
136:245–251.
33. Ensina, L. F., A. E. de Lacerda, D.M. de Andrade, L.Machado,
I. Camelo-Nunes, and D. Sole. 2014. Drug-induced anaphy-
laxis in children: nonsteroidal anti-inflammatory drugs and
drug provocation test. J. Allergy Clin. Immunol. 2:825.
34. Blanca-Lopez, N., J. A. Cornejo-Garcı´a, M. C. Plaza-Seron, I.
Dona, M. J. Torres-Jaen, G. Canto, L. Padilla-Espana, M.
Kidon, J. R. Perkins, andM. Blanca. 2015. Hypersensitivity to
nonsteroidal anti-inflammatory drugs in children and
adolescents: cross-Intolerance reactions. J. Investig. Allergol.
Clin. Immunol. 25:259–269.
35. Sanchez-Borges, M., E. Capriles-Behrens, and F. Caballero-
Fonseca. 2004. Hypersensitivity to non-steroidal anti-inflamma-
tory drugs in childhood. Pediatr. Allergy Immunol. 15:376–380.
36. Renaudin, J. M., E. Beaudouin, C. Ponvert, P. Demoly, and
D. A. Moneret-Vautrin. 2013. Severe drug-induced anaphy-
laxis: analysis of 333 cases recorded by the Allergy Vigilance
Network from 2002 to 2010. Allergy 68:929–937.
37. Ben-Shoshan,M., and A. E. Clarke. Anaphylaxis: past, present
and future. 2011. Anaphylaxis: past, present and future.
Allergy 66:1–14.
38. Khan, F. S., and M. E. Weiss. 2013. Skin testing for Beta-
lactam antibiotics: impact of the availability of a major
determinant. Curr. Allergy Asthma Rep. 13:64–71.
39. Idsoe, O., T. Guthe, R. R. Willcox, and A. L. de Weck. 1968.
Nature and extent of penicillin side-reactions, with particular
reference to fatalities from anaphylactic shock. Bull. World
Health Organ. 38:159–188.
40. Alvarez Ferrero, M. M., T. B. Vree, A. M. Baars, and T. J.
Slooff. 1993. Plasma and bone concentrations of cefuroxime
and flucloxacillin. Oral versus parenteral administration in 20
arthroplasties. Acta Orthop. Scand. 64:525–529.
41. Leone, R., A. Conforti, M. Venegoni, D.Motola, U.Moretti, I.
Meneghelli, A. Cocci, G. Sangiorgi Cellini, S. Scotto, and N.
Montanari. 2005. Drug-induced anaphylaxis: case/non-case
study based on an italian pharmacovigilance database. Drug
Saf. 28:547–556.
SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
Table S1. Characteristics of Prospective versus Retrospective
Patients Presenting to the Emergency Department with
Drug-Induced Anaphylaxis.
Table S2. Follow-up for Diagnosis of Drug Trigger by
Allergy Tests.
Table S3. Factors Associated with Severe Reactions for All
Drugs in Pediatric Patients.
Table S4. Factors Associated with Severe Reactions for All
Drugs in Adult Patients.
Table S5. Factors Associated with Allergy Assessment by and
Allergist in Pediatric Patients.
Table S6. Factors Associated with an Established Allergy by
and Allergist in Pediatric Patients.
Table S7. Characteristics of Pediatric Patients assessed by an
allergist and underwent testing vs. patients that were not
assessed by an allergist.
Table S8. Characteristics of Adult Patients assessed by an
allergist and underwent testing vs. patients that were not
assessed by an allergist.
Drug-induced anaphylaxis in children and adults S. Gabrielli et al.
12 © 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.
